Morepen Laboratories Limited, a leading player in the Medical Devices and Pharmaceutical business, announces its outstanding financial performance for Q1 FY2025. The company has posted net revenue of Rs. 458.64 crore in Q1 FY25 as compared to Rs. 403.46 crore in Q1 FY24, reflecting a growth of 14 per cent. Proft After Tax (PAT) stood at Rs. 36.17 crore as compared to Rs. 14.63 crore, posting a growth of 147 per cent.

This announcement follows a week after the successful completion of a Rs. 200 crore fundraise through Qualified Institutional Placements (QIP) on August 5, 2024.

Sushil Suri, Chairman and Managing Director of Morepen Laboratories, commented on the QIP, stating, “This strategic fundraise marks a pivotal point in the company’s growth journey. With the influx of this new capital, we will accelerate our capacity expansion plans and broaden our market reach.”

He further added, “With this fresh infusion of capital, the company can clearly focus on its two growth engines – Medical Devices & Pharma – and reposition itself for growth in select categories with an end-to-end supply chain from manufacturing to marketing. We will have an increased focus on research and backward integration, fostering innovation and cost reduction, thereby positioning the company as a reliable partner for global outsourcing in both the Medical Devices and Pharma sectors for export markets.”